Category: Pharma
Real World Data to Real World Evidence
From Real-World Data to Real-World Evidence: The Role of AI & FDA Relevance in Shaping the Future of Evidence Generation In today’s data-rich healthcare ecosystem, Real-World Data (RWD) is increasingly viewed as a critical asset, but alone, it’s not enough. The real value emerges when RWD is transformed into Real-World Evidence (RWE) that supports regulatory…
AI for Predicting Market Access Barriers in Rare Diseases
AI for Predicting Market Access Barriers in Rare Diseases Predicting market access barriers in rare diseases is a complex process. AI is helping simplify this process by identifying regulatory, pricing, and reimbursement challenges before they emerge. This article explores how AI can support pharma and biotech companies in improving market access planning for rare disease…
Drug Value with RWE and Role of AI in EU’s JCA
Drug Value with Real-World Evidence (RWE): Opportunities, Challenges, and the Role of AI in EU’s Joint Clinical Assessment (JCA) What is Real-World Evidence and Why It Matters in the EU HTA Landscape Real-World Evidence (RWE) refers to health data gathered outside of traditional clinical trials. It comes from sources like electronic health records, patient registries,…
Pharma Market Access 2025: HTA, U.S. Drug Pricing, and Tariffs
Global Pharma Market Access Under Pressure Pharma market access is no longer just a regulatory hurdle, it’s a geopolitical challenge. With the EU’s new HTA regulation, U.S. pricing reforms, potential Trump tariffs, and legislative shifts in key markets, pharmaceutical access is facing cross-border disruption. Manufacturers must realign their strategies to sustain revenue and reach patients.…
Geo-Competition, RWE, and the Global Policy Storm
Pharma Market Access in 2025: Geo-Competition, RWE, and the Global Policy Storm In 2025, pharma market access is no longer just about clinical evidence and pricing. It’s now a geopolitical chessboard—where real-world evidence (RWE), health technology assessment (HTA), and policy shifts like U.S. tariffs are shaping which medicines reach patients and how fast. Join us…
Will Real-World Evidence (RWE), Decide Your Drug’s Price in 2025?
Real-World Evidence (RWE) Will Decide Your Drug’s Price in 2025 Drug pricing in 2025 is no longer driven solely by clinical trial data. Health authorities and payers now demand proof that drugs perform well in everyday use. Real-World Evidence (RWE) has become the backbone of value-based pricing. Its ability to reflect how patients respond outside…
Why Global Health Agencies Are Demanding RWE in 2025
Why Global Health Agencies Are Demanding Real-World Evidence in 2025 And What It Means for Market Access In 2025, healthcare is no longer defined by clinical trial results alone. Across the globe, regulatory bodies and health technology assessment (HTA) agencies are making one thing crystal clear: Real-World Evidence (RWE) is now a non-negotiable requirement for…
How RWE is Revolutionizing HTA in 2025
How Real-World Evidence (RWE) is Revolutionizing Health Technology Assessments (HTAs) in 2025 In 2025, the convergence of Real-World Evidence (RWE) and Health Technology Assessments (HTAs) is not just a trend, it’s a transformative shift in how healthcare systems evaluate and adopt innovation. As the demand grows for faster, more personalized, and cost-effective healthcare, RWE is…
How Generative AI & Wearables Transforming RWE and Market Access
How Generative AI and Wearables Are Redefining Real-World Evidence (RWE) and Market Access in 2025 In 2025, the healthcare industry is undergoing a profound transformation, driven by the dynamic convergence of Generative AI and wearable technologies. These innovations are not just influencing how data is gathered they are fundamentally reshaping the way Real-World Evidence (RWE)…
The Future of Pharma
The Future of Pharma: How Real-World Evidence & AI Are Shaping Market Access in 2025 Why 2025 Is the Breakthrough Year for Real-World Evidence (RWE)? In 2025, AI-driven healthcare and real-world data (RWD) are transforming how treatments are evaluated, approved, and accessed across global markets. Traditional clinical trials are no longer enough. Pharma companies are…
